AMLX
Price
$14.29
Change
-$0.56 (-3.77%)
Updated
Jan 30 closing price
Capitalization
1.57B
59 days until earnings call
Intraday BUY SELL Signals
CRVS
Price
$20.70
Change
-$0.24 (-1.15%)
Updated
Jan 30 closing price
Capitalization
1.74B
32 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMLX vs CRVS

Header iconAMLX vs CRVS Comparison
Open Charts AMLX vs CRVSBanner chart's image
Amylyx Pharmaceuticals
Price$14.29
Change-$0.56 (-3.77%)
Volume$2.26M
Capitalization1.57B
Corvus Pharmaceuticals
Price$20.70
Change-$0.24 (-1.15%)
Volume$2.43M
Capitalization1.74B
AMLX vs CRVS Comparison Chart in %
AMLX
Daily Signal:
Gain/Loss:
CRVS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMLX vs. CRVS commentary
Feb 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and CRVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 02, 2026
Stock price -- (AMLX: $14.29 vs. CRVS: $20.70)
Brand notoriety: AMLX and CRVS are both not notable
AMLX represents the Pharmaceuticals: Generic, while CRVS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 137% vs. CRVS: 56%
Market capitalization -- AMLX: $1.57B vs. CRVS: $1.74B
AMLX [@Pharmaceuticals: Generic] is valued at $1.57B. CRVS’s [@Biotechnology] market capitalization is $1.74B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.31B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $119.22B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.71B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileCRVS’s FA Score has 1 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • CRVS’s FA Score: 1 green, 4 red.
According to our system of comparison, CRVS is a better buy in the long-term than AMLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 5 TA indicator(s) are bullish while CRVS’s TA Score has 5 bullish TA indicator(s).

  • AMLX’s TA Score: 5 bullish, 5 bearish.
  • CRVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both AMLX and CRVS are a good buy in the short-term.

Price Growth

AMLX (@Pharmaceuticals: Generic) experienced а -9.33% price change this week, while CRVS (@Biotechnology) price change was -17.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.16%. For the same industry, the average monthly price growth was +0.60%, and the average quarterly price growth was +16.95%.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.27%. For the same industry, the average monthly price growth was +3.46%, and the average quarterly price growth was +33.81%.

Reported Earning Dates

AMLX is expected to report earnings on Apr 01, 2026.

CRVS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($1.74B) has a higher market cap than AMLX($1.57B). CRVS YTD gains are higher at: 168.831 vs. AMLX (18.295). CRVS has higher annual earnings (EBITDA): -38.76M vs. AMLX (-156.76M). AMLX has more cash in the bank: 344M vs. CRVS (65.7M). CRVS has less debt than AMLX: CRVS (1.01M) vs AMLX (5.94M). CRVS has higher revenues than AMLX: CRVS (0) vs AMLX (-665K).
AMLXCRVSAMLX / CRVS
Capitalization1.57B1.74B90%
EBITDA-156.76M-38.76M404%
Gain YTD18.295168.83111%
P/E Ratio2.69N/A-
Revenue-665K0-
Total Cash344M65.7M524%
Total Debt5.94M1.01M587%
FUNDAMENTALS RATINGS
CRVS: Fundamental Ratings
CRVS
OUTLOOK RATING
1..100
96
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
22
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMLXCRVS
RSI
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
AMLX
Daily Signal:
Gain/Loss:
CRVS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HBLTX14.94N/A
N/A
Hartford Balanced Income R5
KGIIX19.33N/A
N/A
Kopernik International I
LCLIX40.54-0.07
-0.17%
ClearBridge Large Cap Value 1
KCGIX23.57-0.17
-0.72%
Knights of Columbus Large Cap Growth I
IOLZX29.08-0.44
-1.49%
ICON Equity Institutional

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been closely correlated with XOMAO. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if AMLX jumps, then XOMAO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
-3.77%
XOMAO - AMLX
68%
Closely correlated
-0.05%
XOMAP - AMLX
51%
Loosely correlated
N/A
OCUL - AMLX
46%
Loosely correlated
-8.14%
LRMR - AMLX
45%
Loosely correlated
-0.84%
RGNX - AMLX
43%
Loosely correlated
-3.79%
More

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with ACRS. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then ACRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-1.15%
ACRS - CRVS
65%
Loosely correlated
+2.33%
RAPT - CRVS
46%
Loosely correlated
+0.09%
RZLT - CRVS
41%
Loosely correlated
+2.77%
AMLX - CRVS
36%
Loosely correlated
-3.77%
MAIA - CRVS
36%
Loosely correlated
+0.84%
More